A Phase 3 Randomized Active-Controlled Double-Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Convent
Brief description of study
We are looking for patients who have been diagnosed with Rheumatoid Arthritis (RA), currently taking a traditional anti-rheumatic drug and have had an inadequate response or intolerance to a biologic therapy. The purpose of this study is to compare the safety and benefit of upadacitinib (ABT-494) 15mg once a day tablets versus abatacept (intravenous infusion) for the treatment of Rheumatoid Arthritis(RA) patients who are currently taking a traditional anti-rheumatic drugs (for example, methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide) and have tried but had an inadequate responseor intolerance to a biologic therapy (for example, adalimumab, etanercept, infliximab). Upadacitinib (ABT-494) is an investigational drug that is being tested but has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). However the FDA has allowed the use of this drug for research. Upadacitinib works by blocking the actions of proteins known as Janus kinases (Jaks).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
